143 related articles for article (PubMed ID: 30677268)
21. Drug initiatives to improve cognitive function.
Marder SR
J Clin Psychiatry; 2006; 67 Suppl 9():31-5; discussion 36-42. PubMed ID: 16965187
[TBL] [Abstract][Full Text] [Related]
22. Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective.
Fenton WS; Stover EL; Insel TR
Psychopharmacology (Berl); 2003 Sep; 169(3-4):365-6. PubMed ID: 12955292
[No Abstract] [Full Text] [Related]
23. Genomics and epigenomics in novel schizophrenia drug discovery: translating animal models to clinical research and back.
Bosia M; Pigoni A; Cavallaro R
Expert Opin Drug Discov; 2015 Feb; 10(2):125-39. PubMed ID: 25345474
[TBL] [Abstract][Full Text] [Related]
24. Editorial: Current Approaches for Antipsychotics in Drug Discovery: Hope Beyond the Dopamine D2 Receptor?
Depoortère R
Curr Pharm Des; 2015; 21(26):3698-9. PubMed ID: 26329354
[No Abstract] [Full Text] [Related]
25. Wayne Fenton's impact on industry.
Breier A; Alphs L; Binneman B
Schizophr Bull; 2007 Sep; 33(5):1154-5. PubMed ID: 17562696
[No Abstract] [Full Text] [Related]
26. Bridging bench and practice: translational research for schizophrenia and other psychotic disorders.
Wang PS; Heinssen R; Oliveri M; Wagner A; Goodman W
Neuropsychopharmacology; 2009 Jan; 34(1):204-12. PubMed ID: 18830238
[TBL] [Abstract][Full Text] [Related]
27. Lacking quality in research: Is behavioral neuroscience affected more than other areas of biomedical science?
Bespalov A; Steckler T
J Neurosci Methods; 2018 Apr; 300():4-9. PubMed ID: 29107620
[TBL] [Abstract][Full Text] [Related]
28. Mental health advocates complain about NIMH priority for AIDS. National Institute of Mental Health.
AIDS Policy Law; 2000 Jan; 15(1):5. PubMed ID: 11367224
[TBL] [Abstract][Full Text] [Related]
29. Mads Krogsgaard Thomsen. Interview by Asher Mullard.
Thomsen MK
Nat Rev Drug Discov; 2014 Feb; 13(2):96-7. PubMed ID: 24481301
[No Abstract] [Full Text] [Related]
30. The MATRICS consensus cognitive battery: what we know 6 years later.
Green MF; Harris JG; Nuechterlein KH
Am J Psychiatry; 2014 Nov; 171(11):1151-4. PubMed ID: 25756630
[No Abstract] [Full Text] [Related]
31. Time for new schizophrenia Rx.
Hyman SE
Science; 2014 Mar; 343(6176):1177. PubMed ID: 24626901
[No Abstract] [Full Text] [Related]
32. NIMH assigns blame for tainted studies.
Barinaga M
Science; 1989 Aug; 245(4920):812. PubMed ID: 2772636
[No Abstract] [Full Text] [Related]
33. Wayne Fenton: impact on food and drug administration.
Laughren T
Schizophr Bull; 2007 Sep; 33(5):1153. PubMed ID: 17578891
[No Abstract] [Full Text] [Related]
34. Derisking Psychiatric Drug Development: The NIMH's Fast Fail Program, A Novel Precompetitive Model.
Grabb MC; Cross AJ; Potter WZ; McCracken JT
J Clin Psychopharmacol; 2016 Oct; 36(5):419-21. PubMed ID: 27404513
[TBL] [Abstract][Full Text] [Related]
35. The NIMH Research Portfolio: An Update.
Torrey EF; Simmons WW; Dailey L
Prim Care Companion CNS Disord; 2023 Aug; 25(4):. PubMed ID: 37549433
[No Abstract] [Full Text] [Related]
36. Pharmacotherapy of schizophrenia: toward a metabolomic-based approach.
Tayeb HO; Murad HA; Rafeeq MM; Tarazi FI
CNS Spectr; 2019 Jun; 24(3):281-286. PubMed ID: 29866209
[TBL] [Abstract][Full Text] [Related]
37. NIMH intramural schizophrenia research.
Schizophr Bull; 1988; 14(2):135-41. PubMed ID: 3201173
[No Abstract] [Full Text] [Related]
38. The Continuing Decline of Clinical Research on Serious Mental Illnesses at NIMH.
Torrey EF; Simmons WW; Hancq ES; Snook J
Psychiatr Serv; 2021 Nov; 72(11):1342-1344. PubMed ID: 33820442
[TBL] [Abstract][Full Text] [Related]
39. NIMH-funded pragmatic trials: moving on.
Wang PS; Insel TR
Neuropsychopharmacology; 2010 Dec; 35(13):2489-90. PubMed ID: 21068745
[No Abstract] [Full Text] [Related]
40. A collaborative approach to targeted treatment development for schizophrenia: a qualitative evaluation of the NIMH-MATRICS project.
Bromley E
Schizophr Bull; 2005 Oct; 31(4):954-61. PubMed ID: 16166607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
